SHASHIKALA VENKATACHALAPATHY: Open Payments
NPI 1669555462 · SALISBURY, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,629 in 113 payments from 15 companies in 2025. Trend: 2023 $1,628 · 2024 $1,444 · 2025 $2,629
Food & beverage: $2,629
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 18 | $567 |
| Neurocrine BioSciences, Inc. | 15 | $389 |
| ABBVIE INC. | 19 | $291 |
| Teva Pharmaceuticals USA, Inc. | 15 | $266 |
| Vanda Pharmaceuticals Inc. | 5 | $228 |
| Alkermes, Inc. | 8 | $201 |
| Lundbeck LLC | 10 | $191 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $113 |
| Otsuka America Pharmaceutical, Inc. | 5 | $110 |
| Janssen Pharmaceuticals, Inc | 3 | $72 |
Products named: COBENFY, INGREZZA, VRAYLAR, ARISTADA, FANAPT, AUSTEDO XR, REXULTI, CAPLYTA.
Industry payments across MD — which companies pay providers there.
